Hemostemix Inc. (CVE:HEM – Get Free Report) fell 19.4% on Wednesday . The company traded as low as C$0.14 and last traded at C$0.15. 215,053 shares traded hands during mid-day trading, a decline of 58% from the average session volume of 513,395 shares. The stock had previously closed at C$0.18.
Hemostemix Price Performance
The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The firm has a market capitalization of C$25.50 million, a price-to-earnings ratio of -5.10 and a beta of 0.20. The stock’s 50 day moving average price is C$0.20 and its two-hundred day moving average price is C$0.12.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Quiet Period Expirations Explained
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- Stock Market Upgrades: What Are They?
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- Consumer Staples Stocks, Explained
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
